Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 May;156(5):555-62.
doi: 10.1530/EJE-06-0753.

The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study

Anna Stern  1 , Gail A Laughlin, Jaclyn Bergstrom, Elizabeth Barrett-Connor
Affiliations

The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study

Anna Stern et al. Eur J Endocrinol. 2007 May.

Abstract

Objective: The role of osteoprotegerin (OPG) and its receptor activator of nuclear factor kappaB legend (RANKL) in the regulation of bone in humans remain unclear. We examined the sex-specific associations of serum OPG, RANKL, and their ratio with bone mineral density (BMD) in older adults.

Design: Participants were 681 community-dwelling adults, ages 45-90 years, who had serum OPG and RANKL measured and bone density scans in 1988-1991, with follow-up scans 5 and/or 10 years later.

Methods: Analyses were sex-specific; women using and not using estrogen were evaluated separately. Cross-sectional analyses used multivariable regression models; longitudinal analyses used repeated measures mixed effects models.

Results: In cross-sectional analyses, age- and weight-adjusted serum OPG levels were significantly positively associated with BMD at the lumbar spine in men, and at the femoral neck, total hip, and lumbar spine in women using estrogen, but not in non-users of estrogen. RANKL concentrations were significantly and inversely associated with BMD in men only, and at the total hip. Neither OPG nor RANKL was significantly associated with bone loss. Results for the RANKL/OPG ratio were the same as those for RANKL alone.

Conclusions: These results suggest a modulatory effect of both endogenous and exogenous sex hormones on the biologic interaction of OPG, RANKL, and bone.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Amgen, Inc. paid for and ran the OPG and RANKL assays. Elizabeth Barrett-Connor is a consultant to an Amgen-sponsored registry designed to study patient compliance with bone-specific medications or hormone therapy. Neither of these activities influenced this manuscript and there is no conflict of interest. All other authors have no conflicts of interest.

Figures

Figure 1
Figure 1
Baseline geometric mean OPG levels by age category for each study group; Rancho Bernardo, California, 1981–1991. Abbreviations: OPG, osteoprotegerin; ET, estrogen therapy. Ap<.05, Bp<.01, Cp<.001 versus age ≤60 years for the corresponding group; * sample size.
See this image and copyright information in PMC

References

    1. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142:5050–5055. - PubMed
    1. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005;90:6323–6331. - PubMed
    1. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone. 2003;32:681–686. - PubMed
    1. Hofbauer LC, Heufelder a E. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med. 2001;79:243–253. - PubMed
    1. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95:3597–3602. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources